Clinical Trials Logo

Coronavirus clinical trials

View clinical trials related to Coronavirus.

Filter by:

NCT ID: NCT04624048 Not yet recruiting - Exercise Clinical Trials

Exercise Influence on COVID-19

Start date: December 4, 2020
Phase:
Study type: Observational

An observational study is carried out in the university population of the University of Salamanca to know the impact of the COVID-19 pandemic and the influence of physical exercise on the severity of symptoms.

NCT ID: NCT04610567 Recruiting - Covid19 Clinical Trials

Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)

Nano-COVID19
Start date: October 27, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The investigators propose a prospective, randomized, double-blind, placebo-controlled study, conducted in two phases. The purpose of the study is to evaluate the safety and efficacy of methotrexate in a cholesterol-rich non-protein nanoparticle (MTX -LDE) in adults diagnosed with mild Coronavirus-19(COVID-19) disease. A total of 100 patients will be randomized to receive MTX-LDE or placebo each 7 days, up to 3 times, during in hospital treatment.

NCT ID: NCT04605926 Withdrawn - Coronavirus Clinical Trials

A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19

EQUINOX
Start date: November 2020
Phase: Phase 3
Study type: Interventional

This is a randomized controlled trial to evaluate the efficacy and safety of itolizumab in subjects hospitalized with COVID-19.

NCT ID: NCT04604769 Completed - Coronavirus Clinical Trials

Perceived Stress Among ICU Medical Staff During COVID-19 Crisis

ICUcovid
Start date: June 26, 2019
Phase:
Study type: Observational

The objective of this study is to compare psychological distress and needs of nurses in ICU before and during coronavirus pandemic.

NCT ID: NCT04581954 Recruiting - Covid19 Clinical Trials

Inflammatory Signal Inhibitors for COVID-19 (MATIS)

MATIS
Start date: October 2, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) study is a two-stage, open-label, randomised controlled trial assessing the efficacy of ruxolitinib (RUX) and fostamatinib (FOS) individually, compared to standard of care in the treatment of COVID-19 pneumonia. The primary outcome is the proportion of hospitalised patients progressing from mild or moderate to severe COVID-19 pneumonia. Patients are treated for 14 days and will receive follow-up assessment at 7, 14 and 28 days after the first study dose. Patients with mild or moderate COVID-19 pneumonia will be recruited. Initially, n=171 (57 per arm) patients will be recruited in Stage 1. Following interim analysis to assess the efficacy and safety of the treatments, approximately n=285 (95 per arm) will be recruited during Stage 2.

NCT ID: NCT04572399 Completed - Coronavirus Clinical Trials

UVA Light Device to Treat COVID-19

Start date: October 30, 2020
Phase: N/A
Study type: Interventional

This pilot study will assess the safety and effectiveness of UV light treatment in hospitalized patients with COVID-19.

NCT ID: NCT04568148 Recruiting - Covid-19 Clinical Trials

COVID-19 Biorepository

Start date: April 15, 2020
Phase:
Study type: Observational

Establish a COVID-19 biorepository to aid in developing our knowledge of the disease.

NCT ID: NCT04566965 Terminated - Covid19 Clinical Trials

Serology to COVID-19 for Recording Exposures and Evaluating Needs

SCREEN
Start date: August 18, 2020
Phase:
Study type: Observational

As the global and pandemic spread of the novel coronavirus (SARS-CoV-2, COVID-19) continues, many knowledge gaps remain with regard to the epidemiology and transmission of infection, as well as the normal immunological responses after viral exposure. Cincinnati had its first confirmed case of COVID-19 on March 14, 2020, and despite extensive shelter-in-place and social distancing efforts, community spread continues at over 150-200 new cases per week. As new residents and fellows arrive in July 2020 to Cincinnati Children's Hospital Medical Center (CCHMC), many of whom come from metropolitan areas across the country, it is imperative that investigators determine the current prevalence of infection, measure the cumulative incidence of infection over the next 12-24 months, investigate the normal antibody patterns after infection, and help elucidate what constitutes a protective immunological response. The investigators have a unique but time-limited opportunity to optimally track the epidemiology and natural history of SARS-CoV-2 infection among trainees at CCHMC, including risk factors for transmission and immunological recovery. SCREEN will investigate epidemiological and immunological features of SARS-CoV-2 virus infection within the cohort of CCHMC residents and fellows who have patient contact. By collecting and analyzing weekly serial samples for SARS-CoV-2 (nasal swab for virus by PCR) and monthly serological exposure (serum antibodies by ELISA), the investigators will determine the prevalence and cumulative incidence of infection by SARS-CoV-2; the investigators will also document the antibody responses over time and identify cases of apparent viral recrudescence or re-infection.

NCT ID: NCT04556149 Completed - Clinical trials for Corona Virus Infection

imPulseā„¢ Una Full-spectrum, Over Clothing E-stethoscope

Start date: October 1, 2020
Phase:
Study type: Observational

This study generates robust clinical data to train ML/AI algorithms of the Sponsor's imPulseā„¢ Una full-spectrum e-stethoscope for digital diagnostic feature synthesis of symptomatic SARS-CoV-2/COVID-19 biosignatures for rapid and accurate mass screening.

NCT ID: NCT04552483 Completed - Covid19 Clinical Trials

Effects of Early Use of Nitazoxanide in Patients With COVID-19

Start date: June 8, 2020
Phase: Phase 2
Study type: Interventional

Multicenter, randomized, placebo-controlled, parallel, blinded, interventional, treatment clinical trial with two arms. Population: 392 Patients with COVID-19 (Coronavirus Disease-19), confirmed by RT-PCR (Real Time polymerase chain reaction), symptomatic in the early phase of the disease. Experimental group: 196 patients, nitazoxanide 500mg 8 / 8 hours for 5 days. Control group: 196 patients, placebo 8/8 hours for 5 days.